(Q24202866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

meta-analysis

0 references

title

Mitoxantrone for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

Filippo Martinelli Boneschi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Laura Vacchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Marco Rovaris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Ruggero Capra

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Giancarlo Comi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

31 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

CD002127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Treatment of multiple sclerosis with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Molecular and biochemical pharmacology of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Linking structural, metabolic and functional changes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Therapy with glatiramer acetate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Decrease in heart ventricular ejection fraction during multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Mitoxantrone (novantrone): a review of experimental and early clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Suppression of demyelination by mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

21 January 2018

Dexrazoxane (ICRF-187).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Secondary leukemias induced by topoisomerase-targeted drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB3

7 January 2021

10.1002/14651858.CD002127.PUB3

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

470181

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23728638%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

470181

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

470181